evocatal draws two new investors as it closes €3.5m Series B round
evocatal GmbH has completed a Series B financing round. All of the company's existing investors took part, along with new investors NRW.BANK and LANXESS.
In realizing the next step of its growth strategy, evocatal has partnered with two new investors: LANXESS and NRW.BANK. The investments from this round of financing will be used to extend the firm’s technology platform as well as its product portfolio. “We will significantly expand our team,” says evocatal CEO Dr. Thorsten Eggert, “and we will also increase our capacities and extend our product portfolio to cover the increasing demand for our products.”
“As the financing round is being wrapped up, we will also be kicking off our Innovation Alliance for the Development of Biocatalysts for the Functionalisation of Polymers (FuPol),” adds Dr. Christian Leggewie, CSO at evocatal. The company is coordinating that major project, which is sponsored by Germany’s Federal Ministry of Education and Research (BMBF). “In the course of this project,” says Leggewie, “evocatal will additionally receive up to €1.4m over the next five years to develop innovative, enzyme-based solutions in the area of polymer modification.”
Most read news
Other news from the department business & finance
These products might interest you
Eclipse by Wyatt Technology
FFF-MALS system for separation and characterization of macromolecules and nanoparticles
The latest and most innovative FFF system designed for highest usability, robustness and data quality
Spinsolve Benchtop NMR by Magritek
Spinsolve Benchtop NMR
Spinsolve is a revolutionary multinuclear NMR spectrometer that provides the best performance
HYPERION II by Bruker
FT-IR and IR laser imaging (QCL) microscope for research and development
Analyze macroscopic samples with microscopic resolution (5 µm) in seconds
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.